IRCT20211004052664N1
Recruiting
Phase 3
Evaluation of the efficacy of Favipiravir in comparison with standard medication on clinical and laboratory findings of COVID-19 patients with moderate severity
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Enrollment
- 80
- Status
- Recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Laboratory covfirmation of COVID\-19 virus by RT\-PCR or imaging findings consistent with COVID\-19
- •Moderate\-severity disease (respiratory rate \<30 per minute, oxygen saturation \> 94% or pulmonaru infiltration \< 50% in both lungs)
- •Age above 14 years
- •Willingness to participate in this study
Exclusion Criteria
- •Immunocompromised patients
- •Consumption of effective drugs in the treatment of COVID\-19 in this clinical course
- •History of severe hypersensitivity or anaphylactic shock
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 3
Evaluation the effects of Favipiravir in COVID-19 patientsCOVID-19 pneumonia.COVID-19, virus identifiedU07.1IRCT20151227025726N14Shahid Beheshti University of Medical Sciences84
Completed
Phase 3
Favipiravir effectiveness in patients undergoing COVID19 Acute respiratory distress syndrome (ARDS)covid positive.Coronavirus infection, unspecifiedB34.2IRCT20150107020592N26Masih Daneshvari Hospital20
Completed
Not Applicable
Investigation on the effect of favipiravir in preventing Ebola virus disease and its safetyEbola virus diseaseJPRN-UMIN000016102ational Center for Global Health and Medicine25
Recruiting
Phase 3
The effects of Favipiravir and Lopinavir/Ritonavir in treatment COVID-19IRCT20200506047323N3Bandare-abbas University of Medical Sciences60
Recruiting
Phase 3
The evaluation of efficacy of Favipiravir in patients with mild to moderate COVID-19IRCT20201005048936N1Dr. Abidi pharmacutical Co.126